Effect of food on the bioavailability of triclabendazole in patients with fascioliasis

被引:38
作者
Lecaillon, JB
Godbillon, J
Campestrini, J
Naquira, C
Miranda, L
Pacheco, R
Mull, R
Poltera, AA
机构
[1] Novartis Pharma, Drug Metab & Pharmacokinet, F-92506 Rueil Malmaison, France
[2] Univ Nacl Mayor San Marcos, Inst Med Trop Daniel A Carrion, Parasitol Sect, Lima 14, Peru
[3] Univ Nacl San ANtonio Abad Del Cuzco, Fac Med, Cuzco, Peru
[4] Univ Nacl San ANtonio Abad Del Cuzco, Fac Biol Sci, Cuzco, Peru
[5] Novartis Pharma AG, Clin Res, Basle, Switzerland
[6] Ciba Geigy AG, Dept Med, Special Projects, CH-4002 Basle, Switzerland
关键词
active metabolite; bioavailability; Fasciola hepatica; food; kinetics; patients;
D O I
10.1046/j.1365-2125.1998.00725.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Preliminary results indicate higher absorption of triclabendazole (TCBZ) administered postprandially. Therefore, the influence of food on the pharmacokinetics of TCBZ and its active sulphoxide (TCBZ-SO) and sulphone (TCBZ-SO2) metabolites was investigated. Methods Two single doses (10 mg kg(-1)) of TCBZ were administered to 20 patients with fascioliasis. Ten patients were first given the drug after a high energy breakfast and then, 48 h later, after an overnight fast. The other 10 patients first received the drug in fasting state and then, 48 h later, after breakfast. A low energy breakfast was served 2 h after drug administration for fasting state. Results Compared with the fasting state, an increased AUC and C-max after food intake (significant, P<0.0001) was shown from the values of TCBZ, TCBZ-SO and TCBZ-SO2. The mean AUC for TCBZ (fasting: 1.55, fed: 5.72 mu mol l(-1) h), TCBZ-SO (fasting: 177, fed: 386 mu mol l(-1) h) and TCBZ-SO2 (fasting: 13.9, fed. 30.5 mu mol l(-1) h) indicated a large availability increase with food and the strong systemic predominance of the active sulphoxide metabolite over the unchanged drug. (All patients were cured at the end of the trial except one who required 2. second course of two postprandial doses of triclabendazole (10 mg kg(-1) each). Tolerability to the treatment among the patients was good. Conclusions The administration of triclabendazole with food is recommended for improved systemic availability in patients with fascioliasis or paragonimiasis.
引用
收藏
页码:601 / 604
页数:4
相关论文
共 13 条
[1]   FASCIOLA-HEPATICA - ACTION INVITRO OF TRICLABENDAZOLE ON IMMATURE AND ADULT STAGES [J].
BENNETT, JL ;
KOHLER, P .
EXPERIMENTAL PARASITOLOGY, 1987, 63 (01) :49-57
[2]  
BOLTON S, 1990, PHARM STAT, pCH11
[3]  
Calvopina M., 1993, Parasitologia al Dia, V17, P44
[4]  
Chen M. G., 1990, Tropical Diseases Bulletin, V87, pR1
[5]   THE KINETICS OF TRICLABENDAZOLE DISPOSITION IN SHEEP [J].
HENNESSY, DR ;
LACEY, E ;
STEEL, JW ;
PRICHARD, RK .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1987, 10 (01) :64-72
[6]   INCREASED SYSTEMIC AVAILABILITY OF ALBENDAZOLE WHEN TAKEN WITH A FATTY MEAL [J].
LANGE, H ;
EGGERS, R ;
BIRCHER, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 34 (03) :315-317
[7]   THE INFLUENCE OF FOOD ON THE PHARMACOKINETICS OF CGP-6140 (AMOCARZINE) AFTER ORAL-ADMINISTRATION OF A 1200 MG SINGLE DOSE TO PATIENTS WITH ONCHOCERCIASIS [J].
LECAILLON, JB ;
DUBOIS, JP ;
SOULA, G ;
PICHARD, E ;
POLTERA, AA ;
GINGER, CD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (04) :629-633
[8]  
LOUTAN L, 1989, LANCET, V2, P383
[9]   THERAPEUTIC EFFECT OF TRICLABENDAZOLE IN PATIENTS WITH PARAGONIMIASIS IN CAMEROON - A PILOT-STUDY [J].
RIPERT, C ;
COUPRIE, B ;
MOYOU, R ;
GAILLARD, F ;
APPRIOU, M ;
TRIBOULEYDURET, J .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1992, 86 (04) :417-417
[10]  
Robinson C. P., 1985, DRUG TODAY, V21, P227